O1385
Ozagrel hydrochloride hydrate
≥98% (HPLC), solid
Sign Into View Organizational & Contract Pricing
All Photos(1)
(E)-3-[4-(Imidazol-1-ylmethyl)phenyl]propenoic acid hydrochloride hydrate, OKY-046
C13H12N2O2 · HCl · xH2O
Recommended Products
Quality Level
Assay
≥98% (HPLC)
form
solid
storage condition
desiccated
color
white to off-white
solubility
H2O: soluble
storage temp.
room temp
SMILES string
O.Cl.OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1
InChI
1S/C13H12N2O2.ClH.H2O/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15;;/h1-8,10H,9H2,(H,16,17);1H;1H2/b6-5+;;
InChI key
OWIZTYOMGVTSDP-TXOOBNKBSA-N
Application
Ozagrel hydrochloride hydrate has been used as a thromboxane synthase inhibitor:
- in high cholesterol-diet rats (HC) to test its effect on arteriolar constriction
- to pre-treat mice to test its effect on lipopolysaccharide (LPS)-induced behavioral changes
- to test its effect on arteriolar vasoconstriction in hyperglycemic mice
Biochem/physiol Actions
Ozagrel is useful in treating lacunar and thrombotic stroke. It blocks vasoconstriction and platelet aggregation. Ozagrel aids in improving the prostacyclin (PGI2)/ thromboxane A2 (TXA2) in the acute phase of cerebral ischemia. It improves endothelial dysfunction in L-methionine-induced hyperhomocysteinemia (HHcy)-induced vascular cognitive impairment and dementia (VCID).
Ozagrel is a selective thromboxane A2 synthase (TXA2) inhibitor.
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Regulatory Information
新产品
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Fundamental & clinical pharmacology, 35(4), 650-666 (2020-10-07)
The present study investigates the effect of ozagrel, a selective thromboxane A2 (TXA2) inhibitor, in rat model of hyperhomocysteinemia (HHcy)-induced vascular cognitive impairment and dementia (VCID). Wistar rats were administered L-methionine (1.7 g/kg/day; p.o. × 8 weeks) to induce VCID. Morris water
Brain research, 1599, 85-92 (2015-01-04)
We investigated the neuroprotective properties of single doses of minocycline and ozagrel when administered prior to stroke. Male Sprague-Dawley rats were assigned randomly to one of the following groups: (1) control (Con) group (n=10), (2) minocycline (Mino) group (n=10), (3)
Microvascular research, 76(3), 217-223 (2008-08-23)
Retinal blood flow decreases early in the progression of diabetic retinopathy; however, the mediators and mechanisms responsible for this decrease have yet to be determined. In this study, diabetes was induced by streptozotocin in rats, and retinal blood flow was
Cerebrovascular diseases (Basel, Switzerland), 27(5), 485-492 (2009-03-27)
Edaravone, a free radical scavenger approved by the Japanese Ministry of Health, Labor and Welfare in 2001 for treating acute ischemic stroke, was recommended by the Japanese Guidelines for the Management of Stroke 2004. While edaravone also has a neuroprotective
Atherosclerosis, 209(2), 415-421 (2009-11-26)
The plasma level of soluble CD40 ligand (sCD40L), which induces pro-inflammatory and pro-atherogenic responses, is known to be elevated in atherosclerotic patients. In this study, we investigated the mechanism of sCD40L release from human platelets, focusing on the involvement of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service